Phase I/ <scp>II</scp> study of multipeptide cancer vaccine <scp>IMA901</scp> after single‐dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long‐term follow up-Reference-Cited by-同舟云学术

Phase I/ II study of multipeptide cancer vaccine IMA901 after single‐dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long‐term follow up

Published:2022-10-28 Issue:2 Volume:30 Page:176-180
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Hongo Fumiya¹^ORCID,Ueda Takashi¹^ORCID,Takaha Natsuki¹,Tamada Satoshi²,Nakatani Tatsuya²,Miki Tsuneharu¹,Ukimura Osamu¹^ORCID

Affiliation:

1. Department of Urology Kyoto Prefectural University of Medicine Kyoto Japan

2. Department of Urology Osaka City University Osaka Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.15077

Reference26 articles.

1. Cancer Statistics, 2006

2. Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 cases

3. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

4. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

5. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial Comment to Phase I/II study of multipeptide cancer vaccine IMA901 after single‐dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long‐term follow up;International Journal of Urology;2022-11-07